Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12120832 | 0.78 | NOS2 (0.42) | NOS3NOS1NOS2ESR1KDM4E | |
| SCHEMBL12120835 | 0.72 | BRD4 (0.36) | NOS3NOS1NOS2ESR1 | |
| SCHEMBL12120836 | 0.71 | NOS3 (0.40) | NOS3NOS1NOS2ESR1 | |
| SCHEMBL26704680 | 0.71 | NOS3 (0.34) | NOS3NOS1NOS2ESR1KDM4E | |
| SCHEMBL12120831 | 0.70 | NOS3 (0.39) | NOS3NOS1NOS2ESR1KDM4E | |
| SCHEMBL27286921 | 0.70 | NOS3 (0.33) | NOS3NOS1NOS2GSRKDM4E | |
| SCHEMBL16477887 | 0.69 | RXRA (0.37) | CYP1A2CYP2D6GSRKDM4EALDH1A1 | |
| SCHEMBL12120830 | 0.69 | FABP3 (0.41) | NOS3NOS1NOS2ESR1 | |
| SCHEMBL18157907 | 0.68 | KDM4E (0.45) | NOS3NOS1NOS2KDM4EALDH1A1 | |
| SCHEMBL1119955 | 0.68 | NOS2 (0.50) | NOS3NOS1NOS2ESR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | NOS3 4820/4885NOS1 4856/4885NOS2 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.